These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12800825)

  • 61. Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection.
    Girard PM; Schneider V; Dehée A; Mariot P; Jacomet C; Delphin N; Damond F; Carcelain G; Autran B; Saimot AG; Nicolas JC; Rozenbaum W
    AIDS; 2001 Jan; 15(2):275-7. PubMed ID: 11216939
    [No Abstract]   [Full Text] [Related]  

  • 62. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
    Lanier ER; Givens N; Stone C; Griffin P; Gibb D; Walker S; Tisdale M; Irlbeck D; Underwood M; St Clair M; Ait-Khaled M
    HIV Med; 2004 Nov; 5(6):394-9. PubMed ID: 15544690
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Amprenavir study results released.
    AIDS Patient Care STDS; 1999 Dec; 13(12):754. PubMed ID: 10743545
    [No Abstract]   [Full Text] [Related]  

  • 64. Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.
    de Truchis P; Force G; Welker Y; Mechali D; Pulik M; Chemlal K; Rouveix E; Devidas A; Praindhui D; Mamet JP;
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):178-82. PubMed ID: 12394796
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Drugs for HIV infection.
    Med Lett Drugs Ther; 2000 Jan; 42(1069):1-6. PubMed ID: 10683666
    [No Abstract]   [Full Text] [Related]  

  • 66. Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.
    d'Ettorre G; Zaffiri L; Ceccarelli G; Andreotti M; Massetti AP; Vella S; Mastroianni CM; Vullo V
    HIV Clin Trials; 2007; 8(3):182-8. PubMed ID: 17621465
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
    Matheron S; Descamps D; Boué F; Livrozet JM; Lafeuillade A; Aquilina C; Troisvallets D; Goetschel A; Brun-Vezinet F; Mamet JP; Thiaux C;
    Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
    Henry K; Erice A; Tierney C; Balfour HH; Fischl MA; Kmack A; Liou SH; Kenton A; Hirsch MS; Phair J; Martinez A; Kahn JO
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):339-49. PubMed ID: 9833742
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Simplified treatments for HIV infection].
    Hirschel B
    Ther Umsch; 2004 Oct; 61(10):619-23. PubMed ID: 15532191
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment of late-state HIV infection.
    Millard PS
    J Fam Pract; 1997 Feb; 44(2):132-4. PubMed ID: 9040512
    [No Abstract]   [Full Text] [Related]  

  • 71. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
    Greig SL; Deeks ED
    Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda.
    Srikantiah P; Walusimbi MN; Kayanja HK; Mayanja-Kizza H; Mugerwa RD; Lin R; Charlebois ED; Boom WH; Whalen CC; Havlir DV
    AIDS; 2007 Sep; 21(14):1972-4. PubMed ID: 17721107
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
    HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
    Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 76. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
    Miller V; Ait-Khaled M; Stone C; Griffin P; Mesogiti D; Cutrell A; Harrigan R; Staszewski S; Katlama C; Pearce G; Tisdale M
    AIDS; 2000 Jan; 14(2):163-71. PubMed ID: 10708287
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
    Orkin C; Stebbing J; Nelson M; Bower M; Johnson M; Mandalia S; Jones R; Moyle G; Fisher M; Gazzard B
    J Antimicrob Chemother; 2005 Feb; 55(2):246-51. PubMed ID: 15608053
    [TBL] [Abstract][Full Text] [Related]  

  • 78. FDA notifications. Tentative approval given for combination of abacavir, lamivudine & zidovudine tablets.
    AIDS Alert; 2009 Sep; 24(9):106. PubMed ID: 19928326
    [No Abstract]   [Full Text] [Related]  

  • 79. Long-term control of viral residual replication under maintenance therapy with Trizivir after a quadruple induction regimen in HIV-1-infected adults (Suburbs trial).
    de Truchis P; Mathez D; Force G; Rouveix E; Khuong MA; Chemlal K; Thiaux C; Leibowitch J
    HIV Clin Trials; 2007; 8(2):102-4. PubMed ID: 17507326
    [No Abstract]   [Full Text] [Related]  

  • 80. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
    Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF;
    HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.